The Clinical Value and Interpretation of Anti-M üllerian Hormone in Women With Cancer

Cancer treatments can be damaging to the ovary, with implications for future fertility and reproductive lifespan. There is therefore a need for a biomarker than can usefully provide an assessment of the ovary and its potential for long-term function after cancer treatment, and ideally also be of value pre-treatment, for the prediction of post-treatment function. In this review we assess the value of anti-Müllerian hormone (AMH) in this context. Measurement of AMH at the time of cancer diagnosis has been shown to be predictive of whether or not there will remain some ovarian function post-treatment in women with breast cancer, in conjunction with age. AMH may however be reduced at the time of diagnosis in some conditions, including lymphoma, but probably not in women with breast cancer unless they are carriers of BRCA1 mutations. Following chemotherapy, AMH is often much reduced compared to pretreatment levels, with recovery dependent on the chemotherapy regimen administered, the woman’s age, and her pretreatment AMH. Recent data show there may be a long duration of relative stability of AMH levels over 10 to 15 years prior to decline rather than a rapid decline for many young women after cancer. Post-treatment AMH may have utility in determining that ovarian function will not recover, contributing to assessment of the need for ovarian suppression in women with hormone-sensitive breast cancer. AMH measurement provides an index of treatment gonadotoxicity, allowing c...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Cancer treatment — and cancer itself — can threaten fertility. This is a tremendously important survivorship issue for many people. As an oncologist, I’m often asked questions about preserving fertility during cancer treatment. If this issue affects you, here is an overview of key options. When should you talk to your cancer team about fertility? Future children may not be foremost on your mind when you are diagnosed with cancer. Soon afterward, though, it’s worth talking to your doctor about fertility issues, if this is important to you now or might one day become important. Your doctor can explain...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Fertility Infertility Source Type: blogs
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
Author Affiliations open 1 McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada 2 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain 3 Universitat Pompeu Fabra (UPF), Barcelona, Spain 4 CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain 5 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada 6 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA 7 Department of Economics, Brigham Young University, Provo, Utah, USA 8 Population Studies Division, Health Canada, Ottawa, Cana...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
It is unknown whether gonadal hormone exposure affects the risk of radiation-associated breast cancer in female Hodgkin lymphoma survivors. We performed a nested-case control study to assess the separate and joint effects of radiation dose to the breast and hormone exposure on breast cancer risk. Risk increased linearly with radiation dose, decreased with shorter duration of ovarian function, and did not appear to be influenced by hormone use among women with treatment-induced early menopause.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
CONCLUSIONS: Our work supports the hypothesis that genetic variation of clock genes might affect cancer risk. These findings also highlight the need for more efforts in this research field in order to fully establish the contribution of clock gene variants to the risk of developing cancer. METHODS: We conducted a systematic review and meta-analysis of the evidence on the association between clock genes' germline variants and the risk of developing cancer. To assess result credibility, summary evidence was graded according to the Venice criteria and false positive report probability (FPRP) was calculated to further vali...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The DOK1 (Downstream of Tyrosine kinase 1) gene is a putative tumor suppressor gene located on human chromosome 2p13 which is frequently rearranged in leukaemia and other human tumours. The DOK1 protein is a member of the Dok protein family comprising seven members. It inhibits MAP kinase activity and displays anti-proliferative activities. The DOK1 gene may act as a tumor suppressor gene in ovarian cancer, Burkitt lymphoma, head and neck cancer (HNC), chronic lymphocytic leukaemia (CLL) and lung cancer by inhibiting cell proliferation. So far there is no study in the literature analyzing the relationship between the DOK1 ...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Other Topics: Poster Presentations - Proffered Abstracts Source Type: research
Authors: Ottanelli S Abstract It is well known that fractures increase the risk of morbidity and mortality. The various mechanisms responsible for bone loss in cancer patients may have a different impact depending on the characteristics of the clinical case and correlates with the therapies used, or caused by the therapies used against cancer. Some hormonal treatments cause hypogonadism, event which contributes to the progressive loss of bone mass. This is detectable in patients with breast cancer receiving determines that estrogen-deprivation and in men with prostate cancer with therapies that determine androgen d...
Source: Clinical Cases in Mineral and Bone Metabolism - Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research
In this study, we assessed the long-term impact of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens on ovarian function in patients with aggressive non-Hodgkin lymphoma (NHL). Patients and methods Long-term survivors after CHOP or CHOP plus etoposide (CHOEP) treatment within the Mabthera International Trial or the NHL-B1 trial of the German NHL Study Group were requested to respond to a questionnaire and to consent to blood sampling for hormone assessment. Results A total of 46 of 81 contacted patients with a median age of 32.5 years at the time of enrolment into the aforementioned clinical...
Source: Annals of Oncology - Category: Cancer & Oncology Authors: Tags: hematologic malignancies Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrinology | Hormones | Lymphoma | Men | Menopause | Ovarian Cancer | Ovaries | Reproduction Medicine | Women